Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study

• Published in: Blood advances Vol. 5; no. 20; pp. 4156 - 4166
• Main Authors: Ito, Ayumu, Nakano, Nobuaki, Tanaka, Takashi, Fuji, Shigeo, Makiyama, Junya, Inoue, Yoshitaka, Choi, Ilseung, Nakamae, Hirohisa, Nagafuji, Koji, Takase, Ken, Machida, Shinichiro, Takahashi, Tsutomu, Sawayama, Yasushi, Kamimura, Tomohiko, Kato, Koji, Kawakita, Toshiro, Ogata, Masao, Sakai, Rika, Shiratori, Souichi, Uchimaru, Kaoru, Inamoto, Yoshihiro, Utsunomiya, Atae, Fukuda, Takahiro
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 26.10.2021; American Society of Hematology
• Subjects: Clinical Trials and Observations; Hematopoietic Stem Cell Transplantation; Humans; Leukemia-Lymphoma, Adult T-Cell; Prospective Studies; Retrospective Studies; Unrelated Donors
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2021004932

Aggressive adult T-cell leukemia/lymphoma (ATL) is a hematological malignancy that is difficult to treat with chemotherapy alone, and allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy. We conducted a multicenter, prospective, observational study to clarify the treatment outcomes of aggressive ATL in the current era. Between 2015 and 2018, 113 patients aged 70 years or younger with newly diagnosed aggressive ATL were enrolled. The median age at diagnosis was 61 years. Treatment outcomes were compared with those of 1792 ATL patients diagnosed between 2000 and 2013 in our previous retrospective study. The inclusion criteria were the same in both studies. The prospective cohort demonstrated better overall survival (OS) than the retrospective cohort (2-year OS, 45% vs 29%, respectively; P < .001), with a much higher proportion of patients receiving allo-HCT (80% vs 34%, respectively; P < .001) and a shorter interval from diagnosis to allo-HCT (median, 128 vs 170 days, respectively; P < .001). Among the 90 patients who received allo-HCT (cord blood, n = 30; HLA-haploidentical related donors, n = 20; other related donors, n = 14; other unrelated donors, n = 26), the 2-year probabilities of OS, non-relapse mortality (NRM), and disease progression were 44%, 23%, and 46%, respectively. OS and NRM did not differ statistically according to donor type. Our results suggest that increased application of allo-HCT improved the survival of patients with aggressive ATL. The use of cord blood or HLA-haploidentical donors may be feasible for aggressive ATL when HLA-matched related donors are unavailable. This study was registered at the UMIN Clinical Trials Registry as #000017672. •The survival of patients with aggressive ATL has improved by increased application of allo-HCT after response to initial chemotherapy.•The use of cord blood or HLA-haploidentical donors may be feasible for aggressive ATL when HLA-matched related donors are unavailable. [Display omitted]